| Objective:To investigate the efficacy and safety of nimotuzumab combined with radiotherapy in high-risk postoperative patients with head and neck squamous cell carcinoma unsuitable for cisplatin.Methods:A total of 10 postoperative patients with high-risk head and neck squamous cell carcinoma admitted to the Department of Oncology of the First Affiliated Hospital of Nanchang University from October 2019 to September 2021 were selected.All the patients were given intensity radiotherapy(IMRT)with the specific dose as follows:Tumor bed area + high-risk lymph node drainage area(60 Gy/30 times),low-risk area(54 Gy/30 times),5 times/week,total of 6 weeks;After the beginning of radiotherapy,nimotuzumab 200 mg was given once a week until the end of radiotherapy for 6 weeks.The toxic and side effects of nimotuzumab combined with radiotherapy were observed and recorded during the treatment,and the short-term efficacy after radiotherapy was evaluated after the completion of all treatments.Results:All patients eligible for inclusion completed 6 cycles of nimotuzumab combined with radiotherapy.The median follow-up time for all patients from enrollment to last follow-up was 10 months(follow-up range: 3 to 15 months).Of the 10 enrolled patients3 died,0 died of treatment-related complications,4 had local regional recurrence,and2 of them had distant metastasis.Kaplan-Meier survival analysis showed a 1-year DFS rate of 60%(95CI:30%-90%).Adverse reactions: thrombocytopenia(grade I 1 case,grade III 1 case);Rash(1 case,grade III),radiation mucositis(5 cases,grade I,2 cases,grade II,2 cases,grade III);Decreased hemoglobin(2 cases of grade II)and impaired liver function(2 cases of grade ⅱ and 2 cases of grade III);Nausea and vomiting(grade Ⅱ 2 cases,grade Ⅲ 1 case).Conclusion:Nimotuzumab plus radiotherapy has certain effectiveness and good safety in the treatment of postoperative head and neck squamous cell carcinoma. |
PDF Full Text Request